These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 34514097)

  • 1. Extending traditional antibody therapies: Novel discoveries in immunotherapy and clinical applications.
    Shin C; Kim SS; Jo YH
    Mol Ther Oncolytics; 2021 Sep; 22():166-179. PubMed ID: 34514097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody and antibody fragments for cancer immunotherapy.
    Chen W; Yuan Y; Jiang X
    J Control Release; 2020 Dec; 328():395-406. PubMed ID: 32853733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives.
    Liu L; Chen J
    Med Rev (2021); 2022 Dec; 2(6):555-569. PubMed ID: 37724258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in the poisoned patient. Overview of present applications and future trends.
    Sullivan JB
    Med Toxicol; 1986; 1(1):47-60. PubMed ID: 3537615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies.
    Majidi J; Barar J; Baradaran B; Abdolalizadeh J; Omidi Y
    Hum Antibodies; 2009; 18(3):81-100. PubMed ID: 19729803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanoma immunotherapy: historical precedents, recent successes and future prospects.
    Raaijmakers MI; Rozati S; Goldinger SM; Widmer DS; Dummer R; Levesque MP
    Immunotherapy; 2013 Feb; 5(2):169-82. PubMed ID: 23413908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
    Luo C; Wang P; He S; Zhu J; Shi Y; Wang J
    Front Oncol; 2022; 12():919072. PubMed ID: 35795050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Cancer Immunotherapies.
    DeLucia DC; Lee JK
    Cancer Treat Res; 2022; 183():1-48. PubMed ID: 35551655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
    Masarova L; Kantarjian H; Garcia-Mannero G; Ravandi F; Sharma P; Daver N
    Adv Exp Med Biol; 2017; 995():73-95. PubMed ID: 28321813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Full-length recombinant antibodies from
    Rashid MH
    MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland.
    Beck A; Wurch T; Reichert JM
    MAbs; 2011; 3(2):111-32. PubMed ID: 21441785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological Therapy of Hematologic Malignancies: Toward a Chemotherapy- free Era.
    Klener P; Etrych T; Klener P
    Curr Med Chem; 2019; 26(6):1002-1018. PubMed ID: 28990505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies.
    Zhang P; Xiong X; Rolfo C; Du X; Zhang Y; Yang H; Russo A; Devenport M; Zhou P; Liu Y; Zheng P
    Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 31991588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.